Variants of bcl-2 specific siRNA for silencing antiapoptotic bcl-2 in pancreatic cancer.

ABSTRACT:

Background and aims

Pancreatic cancer remains a devastating diagnosis with only limited therapeutic options. Specific inhibition of expression of target genes has become possible using small interfering (si) RNAs. We therefore investigated how far siRNA specific for bcl-2 may serve as a therapeutic option for pancreatic cancer in vitro and in vivo.

Methods

siRNAs targeting two different regions in the bcl-2 gene were transfected to YAP C and DAN G pancreatic carcinoma cells and human foreskin fibroblasts. Permutations were generated by changing 3' and 5' overhangs and varying the length of the paired RNA duplex. Transfection efficacy was determined using FITC labelled siRNAs and fluorescence microscopy. Cell survival and apoptosis were quantified at 24-120 hours. Pancreatic

SUBMITTER: Ocker M 

PROVIDER: S-EPMC1774673 | biostudies-literature | 2005 Sep

REPOSITORIES: biostudies-literature